End-of-day quote
Other stock markets
|
||
- USD | - |
03-28 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-05 | Top Midday Gainers | MT |
Sales 2024 * | 59.17M 4.73B | Sales 2025 * | 88.09M 7.04B | Capitalization | 31.04M 2.48B |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | 11M 879M | EV / Sales 2024 * | 0.52 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.35 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
7.03
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.99% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 01/04/19 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 31/08/18 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 31/12/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 01/04/19 |
Yue Wu
BRD | Director/Board Member | 62 | 31/03/13 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 20/03/23 |
1st Jan change | Capi. | |
---|---|---|
+33.25% | 699B | |
+26.16% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.92% | 236B | |
+4.83% | 198B | |
-10.27% | 194B | |
-3.69% | 149B |